Published in Hepatitis Weekly, November 29th, 1999
According to Martin Becker, PhD, XTL, "XTL's Trimera(XTL) HCV disease model offers drug development companies a breakthrough, in vivo system that could significantly accelerate the development and commercialization of new drugs to treat hepatitis C, a serious infectious disease that is responsible for an estimated 8,000 deaths annually in the U.S."
The companies will use XTL's Trimera(XTL) system,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.